Case Filed: Mar 07, 2013
Case Closed: Sep 20, 2013
Court: New Jersey District Court
Judge: Jerome B. Simandle
Case Summary:
Merck Sharp & Dohme (MSD) and
Bristol-Myers Squibb (BMS) jointly filed a patent infringement suit against
Hetero, India-based pharmaceuticals claiming that three of their patents
related to HIV drug were infringed. The
patents involved in suit are:
- US6673372 entitled Crystalline Efavirenz, issued on Jan 06, 2004 and expiring* by Jun 10, 2019
- US6639071 and US6939964 both entitled Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-ben zoxazin-2-one, issued on Oct 28, 2003 and Sep 06, 2005, both expiring* by Jan 20, 2018
The ‘372 patent is currently
assigned+
to Bristol-Myers Squibb and the ‘071 and ‘964 patents are currently assigned+
to MSD (source: MaxVal’s Assignment
Database).
The Court document said defendant
by filing an abbreviated new drug application (ANDA) no. 204411 with FDA seeking
approval to engage in commercial manufacturing of the drug containing 600 mg
efavirenz tablets, a generic version of BMS’s Sustiva® drug product have
infringed ‘372, ‘071 and ‘964 patents.
BMS currently holds± the new drug application (NDA) no. 021360
(source: MaxVal’s Patent
Marker), approved by FDA
for 600 mg efavirenz tablets in Feb 1, 2002, which is sold under the trade name
Sustiva. It was originally produced by DuPont Pharmaceuticals and is now
manufactured by Bristol-Myers Squibb for sale in the United States. The trade
name Stocrin is used by Merck Sharp & Dohme, who market the same drug in
Europe and many other parts of the world. This drug is used with other HIV
medications to help control HIV infection, which lowers the chance of getting
HIV complications (such as new infections, cancer).
As per the complaint, “Defendants
have committed an act of infringement of the patents and such infringement will
cause Plaintiffs irreparable harm unless enjoined by this Court.” So, plaintiffs wanted judgment that defendant
has infringed the patents and an injunction barring their products until
expiration of the patents, along with costs and expenses.
It appears that the parties filed
a stipulation and proposed order of dismissal, pursuant to which the Court
granted and ordered all claims and counterclaims asserted in this civil action
be dismissed without prejudice. Each party will bear their own costs and
expenses.
Plaintiffs have sued other
generic version manufacturers of efavirenz including Cipla, Aurobindo and a few
others.
See
1:13-cv-01402 for
more details. To get alerts on cases filed/closed, subscribe to our Litigation
Alerts.
* Expected
expiration date. Patent Term
Estimator is a free web-based tool that automatically calculates patent
terms and expiration dates for U.S. utility patents.
+ MaxVal offers Patent Assignment Alert service
where subscribers receive email alerts when assignments relating to target
applications, patents or entities of interest are recorded.
± Patent
Marker provides an online environment where patentees can virtually mark
products and search products for patent-related information.
No comments:
Post a Comment